Apellis Pharmaceuticals, Inc. APLS NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) reported total assets of $1.08B and total liabilities of $705.11M for quarter ending 2025-12-31, resulting in total equity of $370.15M.

The company held $467.76M in cash and short-term investments. Total debt stood at $486.31M, with net debt of $18.55M. The Debt-to-Equity (D/E) ratio was 1.31 (moderate).

Current ratio is 3.14, indicating strong short-term liquidity. Interest coverage is -4.7x (weak).

Criteria supported by this page:

• HEALTH (50/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (65/100) — Total assets $1.08B and equity $370.15M support the company's competitive scale
• VALUE (18/100) — Debt-to-Equity 1.31 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 48/100 with 1/7 criteria passed.